[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ: Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat; 2010 Oct;123(3):819-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.
  • Brain gray matter alterations have been reported in cross-sectional magnetic resonance imaging (MRI) studies of breast cancer patients after cancer treatment.
  • Here we report the first prospective MRI study of women undergoing treatment for breast cancer, with or without chemotherapy, as well as healthy controls.
  • We hypothesized that chemotherapy-associated changes in gray matter density would be detectable 1 month after treatment, with partial recovery 1 year later.
  • Participants included breast cancer patients treated with (CTx+, N = 17) or without (CTx-, N = 12) chemotherapy and matched healthy controls (N = 18).
  • MRI scans were acquired at baseline (after surgery but before radiation, chemotherapy, and/or anti-estrogen treatment), 1 month after completion of chemotherapy (M1), and 1 year later (Y1).
  • Voxel-based morphometry (VBM) was used to evaluate gray matter density differences between groups and over time.
  • Group-by-time interactions showed declines from baseline to M1 in both cancer groups relative to controls.
  • Within-group analyses indicated that at M1 relative to baseline the CTx+ group had decreased gray matter density in bilateral frontal, temporal, and cerebellar regions and right thalamus.
  • Findings were not attributable to recency of cancer surgery, disease stage, psychiatric symptoms, psychotropic medication use, or hormonal treatment status.
  • This study is the first to use a prospective, longitudinal approach to document decreased brain gray matter density shortly after breast cancer chemotherapy and its course of recovery over time.
  • These gray matter alterations appear primarily related to the effects of chemotherapy, rather than solely reflecting host factors, the cancer disease process, or effects of other cancer treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain / drug effects. Breast Neoplasms / drug therapy. Magnetic Resonance Imaging
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Longitudinal Studies. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2007 Jan 1;109(1):146-56 [17131349.001]
  • [Cites] Neurology. 2006 Oct 10;67(7):1221-4 [17030756.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):192-201 [17318212.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;103(3):303-11 [17009108.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3866-70 [17761972.001]
  • [Cites] Neurosci Res. 2007 Dec;59(4):383-9 [17923164.001]
  • [Cites] Neurosci Lett. 2007 Dec 11;429(1):7-11 [17996370.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):623-9 [17974553.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jul;110(1):143-52 [17674194.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2431-9 [18823033.001]
  • [Cites] Cancer J. 2008 Nov-Dec;14(6):396-400 [19060604.001]
  • [Cites] J Cancer Surviv. 2008 Dec;2(4):275-82 [18923905.001]
  • [Cites] Lancet Oncol. 2008 Oct;9(10):953-61 [18768369.001]
  • [Cites] J Clin Exp Neuropsychol. 2009 Jan;31(1):73-89 [18608651.001]
  • [Cites] J Psychiatr Res. 2009 Jan;43(3):331-40 [18486147.001]
  • [Cites] Psychooncology. 2009 Feb;18(2):134-43 [18551510.001]
  • [Cites] Cancer. 2009 Apr 15;115(8):1776-83 [19224550.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(1):113-23 [18629633.001]
  • [Cites] Annu Rev Neurosci. 2009;32:413-34 [19555291.001]
  • [Cites] Psychooncology. 2009 Jul;18(7):775-82 [19061196.001]
  • [Cites] Curr Alzheimer Res. 2009 Aug;6(4):347-61 [19689234.001]
  • [Cites] Neuroimage. 2010 Jan 1;49(1):71-9 [19683060.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):48-54 [20160209.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1294-300 [20142601.001]
  • [Cites] Neuroimage. 2001 Jul;14(1 Pt 1):21-36 [11525331.001]
  • [Cites] Neuroimage. 2000 Jun;11(6 Pt 1):805-21 [10860804.001]
  • [Cites] Brain Res Bull. 2008 Nov 25;77(5):237-40 [18755251.001]
  • [Cites] Neuroimage. 2001 Dec;14(6):1238-43 [11707080.001]
  • [Cites] Semin Clin Neuropsychiatry. 2003 Oct;8(4):201-16 [14613048.001]
  • [Cites] J Int Neuropsychol Soc. 2003 Nov;9(7):967-82 [14738279.001]
  • [Cites] Neuroimage. 2004 Jan;21(1):364-71 [14741674.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):466-75 [15274059.001]
  • [Cites] J Clin Exp Neuropsychol. 2004 Oct;26(7):955-69 [15742545.001]
  • [Cites] Clin Neuropsychol. 2006 Feb;20(1):76-89 [16410227.001]
  • [Cites] Biol Psychiatry. 2006 Apr 15;59(8):707-12 [16213471.001]
  • [Cites] Neurology. 2006 Sep 12;67(5):834-42 [16966547.001]
  • [Cites] Neurotoxicology. 2007 Jan;28(1):83-92 [16973216.001]
  • (PMID = 20690040.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / P30 AG010133; United States / NIA NIH HHS / AG / R01 AG019771; United States / NCI NIH HHS / CA / R01 CA087845; United States / NCI NIH HHS / CA / R01 CA101318; United States / NCI NIH HHS / CA / R01 CA101318; United States / NCI NIH HHS / CA / R25 CA117865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS465360; NLM/ PMC3661415
  •  go-up   go-down


2. Uchino M, Kitajima S, Miyazaki C, Shibata I, Miura M: Bilateral thalamic glioma--case report. Neurol Med Chir (Tokyo); 2002 Oct;42(10):443-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral thalamic glioma--case report.
  • A 35-year-old woman presented with a bilateral thalamic glioma manifesting as dysesthesia over the left side of the body and mental deterioration.
  • Radiotherapy and chemotherapy failed to arrest tumor growth.
  • Magnetic resonance imaging and clinical findings support the view that bilateral thalamic gliomas represent a distinct clinicopathologic entity among thalamic tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Thalamus / pathology
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Magnetic Resonance Imaging. Personality Disorders / diagnosis. Personality Disorders / etiology. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12416569.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


3. Nass R, Boyce L, Leventhal F, Levine B, Allen J, Maxfield C, Salsberg D, Sarno M, George A: Acquired aphasia in children after surgical resection of left-thalamic tumors. Dev Med Child Neurol; 2000 Sep;42(9):580-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired aphasia in children after surgical resection of left-thalamic tumors.
  • Five children (three males, two females; four right-, one left-handed; age range 6 to 14 years) who developed aphasia after gross-total excision of left predominantly thalamic tumors are reported.
  • In the months after surgery, three children improved while receiving radiation and/or chemotherapy, although none recovered completely.
  • Two patients with malignant tumors developed worsening aphasia when the tumor recurred, and later died.
  • The wide range of deficits in these children highlights the importance of the thalamus and other subcortical structures in developing cognition.
  • [MeSH-major] Aphasia / etiology. Brain Neoplasms / surgery. Postoperative Complications. Thalamic Diseases / surgery


Advertisement
4. Shingu T, Akiyama Y, Daisu M, Maruyama N, Matsumoto Y, Miyazaki T, Nagai H, Yamamoto Y, Yamasaki T, Yoshida M, Maruyama R, Moritake K: Symptomatic hemorrhage associated with recurrent pilocytic astrocytoma with granulation tissue--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):222-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic hemorrhage associated with recurrent pilocytic astrocytoma with granulation tissue--case report.
  • A 51-year-old woman had been followed up for 10 years for recurrence of pilocytic astrocytoma 5 years after the initial treatment consisting of subtotal resection, chemotherapy, and radiation therapy.
  • Computed tomography and T(2)*-weighted magnetic resonance imaging revealed hemorrhage in the tumor located in the right basal ganglia, thalamus, and hypothalamus.
  • Histological examination confirmed recurrent pilocytic astrocytoma with organizing hematoma and granulation tissue.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Hemorrhage / etiology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Female. Granulation Tissue / pathology. Humans

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527050.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Coelho Neto M, Ramina R, de Meneses MS, Arruda WO, Milano JB: Peritoneal dissemination from central neurocytoma: case report. Arq Neuropsiquiatr; 2003 Dec;61(4):1030-4
Genetic Alliance. consumer health - Central Neurocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Central neurocytoma is a low grade tumor of neuroglial origin and a relatively new histological entity.
  • CASE: A six years-old boy with recurrent neurocytoma of III ventricle and left thalamus showed fast growth of tumor rest and ascites three and a half years after subtotal removal of the lesion.
  • Tumor cells were identified in the ascitic fluid and implanted in the peritoneum.
  • Chemotherapy was initiated immediately after diagnosis of peritoneal dissemination (etoposide, carboplatin, doxorubicin and cyclophosphamide).
  • The patient developed metabolic imbalance and respiratory failure due to rapid formation of ascitic fluid and died 3 days after the diagnosis of peritoneal dissemination was established.
  • CONCLUSION: Central neurocytoma is a low grade tumor with low values of the proliferative index in the majority of cases.
  • In spite of that, some tumors may present a very aggressive behavior and extraneural dissemination.
  • Evaluation of proliferative index may be a guideline parameter for planning adjuvant therapies after surgical treatment in selected cases.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Neurocytoma / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm, Residual. Peritoneum. Reoperation. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14762613.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, Castillo MR, Longchong M, Iznaga N, Lage A: Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev; 2009 Jul;11(3):27-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007.
  • Introduction Nimotuzumab, developed in Cuba, is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR).
  • It has been evaluated in malignant brain tumors in adults and children, and shown to be therapeutically safe and effective in terms of increased survival and improved quality of life.
  • Objective Describe nimotuzumab's safety profile and clinical benefits in terms of disease control and survival in pediatric patients with progressive or recurrent primary brain tumors who were included in an expanded access program.
  • Between December 2005 and December 2007, 22 patients were included, all of whom had an histological and/or radiological diagnosis of progressive or recurrent primary brain tumor, classified as high-grade malignant glioblastoma (n=6), diffuse brain stem glioma (n=6), ependymoblastoma (n=5), low-grade glioma (n=4), or thalamic tumor (n=1); life expectancy of at least 4 weeks; and a Karnofsky or Lansky Performance Status score of ≥50.
  • Therapeutic protocols were followed for administration as monotherapy or in combination with chemotherapy and/or radiotherapy.
  • Results Nimotuzumab was well tolerated in all therapeutic modalities, even with prolonged exposure.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21483304.001).
  • [ISSN] 1555-7960
  • [Journal-full-title] MEDICC review
  • [ISO-abbreviation] MEDICC Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Song JH, Kong DS, Seol HJ, Shin HJ: Transventricular Biopsy of Brain Tumor without Hydrocephalus Using Neuroendoscopy with Navigation. J Korean Neurosurg Soc; 2010 Jun;47(6):415-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transventricular Biopsy of Brain Tumor without Hydrocephalus Using Neuroendoscopy with Navigation.
  • OBJECTIVE: It is usually difficult to perform the neuroendoscopic procedure in patients without hydrocephalus due to difficulties with ventricular cannulation.
  • The purpose of this study was to find out the value of navigation guided neuroendoscopic biopsy in patients with peri- or intraventricular tumors without hydrocephalus.
  • METHODS: Six patients with brain tumors without hydrocephalus underwent navigation-guided neuroendoscopic biopsy.
  • The procedure was indicated for verification of the histological diagnosis of the neoplasm, which was planned to be treated by chemotherapy and/or radiotherapy as the first line treatment, or establishment of the pathological diagnosis for further choice of the most appropriate treatment strategy.
  • The histopathologic diagnosis was established in all of 6 patients : 2 germinomas, 2 astrocytomas, 1 dysembryoplastic neuroepithelial tumor and 1 pineocytoma.
  • The tumor biopsy sites were pineal gland (n = 2), suprasellar area (n = 2), subcallosal area (n = 1) and thalamus (n = 1).
  • There were no operative complications related to the endoscopic procedure.
  • CONCLUSION: Endoscopic biopsy or resection of peri- or intraventricular tumors in patients without hydrocephalus is feasible.
  • Image-guided neuroendoscopic procedure improved the accuracy of the endoscopic approach and minimized brain trauma.
  • The absence of ventriculomegaly in patients with brain tumor may not be served as a contraindication to endoscopic tumor biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1978 Mar-Apr;2(2):110-3 [732959.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1235-9 [19002372.001]
  • [Cites] Minim Invasive Neurosurg. 1995 Jun;38(2):79-84 [7583365.001]
  • [Cites] Acta Neurochir Suppl. 1994;61:76-8 [7771229.001]
  • [Cites] Childs Nerv Syst. 1994 Apr;10(3):162-6 [8044811.001]
  • [Cites] Pediatr Neurosurg. 1993 May-Jun;19(3):127-34 [8499325.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(1):12-20; discussion 20-1 [9059706.001]
  • [Cites] Minim Invasive Neurosurg. 1997 Dec;40(4):139-43 [9477403.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):496-505 [9488304.001]
  • [Cites] Neurosurgery. 1998 Jun;42(6):1288-94; discussion 1294-6 [9632187.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;68(1-4 Pt 1):80-9 [9711700.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):1062-8 [9833841.001]
  • [Cites] Neurosurgery. 1999 May;44(5):1103-9; discussion 1109-11 [10232544.001]
  • [Cites] J Neurosurg. 2000 Aug;93(2):245-53 [10930010.001]
  • [Cites] Pediatr Neurosurg. 2000 Sep;33(3):132-7 [11096360.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):72-9 [11147902.001]
  • [Cites] Br J Neurosurg. 2001 Aug;15(4):305-11 [11599445.001]
  • [Cites] Br J Neurosurg. 2002 Oct;16(5):465-70 [12498490.001]
  • [Cites] Neurosurgery. 2003 Mar;52(3):525-33; discussion 532-3 [12590676.001]
  • [Cites] Presse Med. 1963 May 18;71:1225-8 [13963492.001]
  • [Cites] Neurosurgery. 2005 Oct;57(4 Suppl):312-8; discussion 312-8 [16234680.001]
  • [Cites] Neurosurg Focus. 1999 Apr 15;6(4):e5 [16681359.001]
  • [Cites] J Neurosurg. 1973 Feb;38(2):251-6 [4694225.001]
  • (PMID = 20617084.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2899026
  • [Keywords] NOTNLM ; Navigation / Neuroendoscopy / Without hydrocephalus
  •  go-up   go-down


8. Iwami K, Arima T, Ooka F, Asai T, Tambara M, Takaoka T: [Bilateral thalamic glioma in an adult: a case report and review of the literature]. No Shinkei Geka; 2009 Mar;37(3):285-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral thalamic glioma in an adult: a case report and review of the literature].
  • We report a case of a 36-year-old woman who had a rare bilateral thalamic glioma (BTG).
  • BTG is a rare variant of thalamic neoplasms, which can be distinguished clinically and radiologically from other gliomas.
  • Death usually occurs within two years after onset, independently of adjuvant therapy such as radiotherapy and chemotherapy.
  • At the time of this writing (5 months after the consultation), there are no neurological symptoms, and no changes on neuroimaging.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Thalamus

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306649.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


9. Walter AW, Gajjar A, Reardon DA, Thompson SJ, Langston JW, Jones-Wallace D, Kun LE, Heideman RL: Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol; 2000 May-Jun;22(3):247-51
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The authors conducted a single-arm, prospective study using tamoxifen and carboplatin for the treatment of children with progressive or symptomatic low-grade gliomas.
  • One patient was excluded after induction chemotherapy because of the diagnosis of a nonmalignant condition.
  • RESULTS: The median age at diagnosis was 5.3 years, the median age at initiation of chemotherapy was 8.3 years.
  • Eight patients had tumors of the hypothalamus/optic pathway, two patients had thalamic tumors, and one patient each had tumors in the temporal lobe, tectum, and brain stem.
  • Tumor histologic findings included fibrillary astrocytoma (n = 2), juvenile pilocytic astrocytoma (n = 6), and oligodendroglioma (n = 1).
  • The best response to therapy was a partial response in two patients, stable disease in nine patients, and progressive disease in two patients.
  • Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas.
  • Nonmyelosuppressive agents such as tamoxifen deserve additional evaluation in the treatment of children with low-grade gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Child. Child, Preschool. Disease Progression. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Female. Humans. Life Tables. Male. Prospective Studies. Protein Kinase C / antagonists & inhibitors. Survival Analysis. Survival Rate. Tamoxifen / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10864056.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P01 CA-23099; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 094ZI81Y45 / Tamoxifen; BG3F62OND5 / Carboplatin; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


10. Allen JC: Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg; 2000 Mar;32(3):154-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1.
  • Optic pathway/hypothalamus gliomas (OPG) arise primarily from a slower-growing juvenile pilocytic astrocytoma, and thalamic gliomas arise primarily from a fibrillary astrocytoma which can become clinically and histologically more aggressive.
  • The major therapeutic challenge for these patients is to maximize their quality of life by preserving visual and endocrine function while minimizing treatment-related morbidity.
  • Treatment is often initiated at diagnosis in infants and toddlers who have a major visual impairment or the diencephalic syndrome.
  • The judicious application of chemotherapy may serve to forestall the need for radiotherapy or surgery.
  • Tumors may grow more slowly or occasionally regress spontaneously.
  • However, over 90% of children with OPG without NF-1 will require some form of therapy.
  • Patients with thalamic gliomas present with a shorter history, often with hydrocephalus.
  • Surgical intervention is often required to relieve intracranial pressure and establish the histologic identity of the tumor.
  • Over 75% of these tumors will become locally aggressive.
  • Current multimodality therapy is relatively ineffective.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Hypothalamic Neoplasms / surgery. Neurofibromatosis 1 / surgery. Thalamic Diseases / surgery
  • [MeSH-minor] Child. Child, Preschool. Humans. Hypothalamus / pathology. Infant. Magnetic Resonance Imaging. Neoadjuvant Therapy. Optic Nerve Glioma / diagnosis. Optic Nerve Glioma / surgery. Thalamus / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10867564.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 21
  •  go-up   go-down


11. Rorke-Adams LB, Portnoy H: Long-term survival of an infant with gliomatosis cerebelli. J Neurosurg Pediatr; 2008 Nov;2(5):346-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is an uncommon but well-established central nervous system neoplasm that occurs primarily in adults.
  • In this report the authors document the surgical treatment of a 13-month-old boy whose tumor arose in the cerebellum and over time extended to the thalamus where its growth halted at age 3 years and 10 months.
  • Aside from 2 partial resections the patient underwent neither radiotherapy nor chemotherapy.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Neoplasms, Neuroepithelial / pathology. Neoplasms, Neuroepithelial / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Infant. Male. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976105.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Bowers DC, Krause TP, Aronson LJ, Barzi A, Burger PC, Carson BS, Weingart JD, Wharam MD, Melhem ER, Cohen KJ: Second surgery for recurrent pilocytic astrocytoma in children. Pediatr Neurosurg; 2001 May;34(5):229-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma (PA) is the most common childhood brain tumor.
  • In cases where the tumor progresses or recurs following primary surgical resection, the appropriate treatment is unclear.
  • Options include chemotherapy, radiation therapy, surgical resection or a combination thereof.
  • Patients were excluded if they received adjuvant chemotherapy or radiation therapy.
  • Tumor locations included: cerebral hemisphere (3), cerebellum (7), optic pathway/hypothalamus (5), thalamus (1) and brainstem (4).
  • The indication for 4 surgeries included an enlarging tumor-associated cyst.
  • Two of 10 tumors after GTR, 0 of 2 tumors after NTR, and 7 of 8 tumors after STR had second recurrence/progression at a mean of 15 months (range 4-33 months) following second surgery.
  • Surgery for tumors or midline structures rarely resulted in a GTR (1 of 10 cases).
  • Surgery for tumors located in the cerebral hemispheres or cerebellum resulted in GTR or NTR in all cases and can result in long periods of progression-free survival without further adjuvant treatment.
  • [MeSH-major] Astrocytoma / surgery. Brain / surgery. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Reoperation / adverse effects. Retrospective Studies. Treatment Outcome


13. Dolendo MC, Lin TP, Tat OH, Chong QT, Timothy LK: Parkinsonism as an unusual presenting symptom of pineal gland teratoma. Pediatr Neurol; 2003 Apr;28(4):310-2
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnostic evaluation revealed hydrocephalus and an immature teratoma of the pineal gland extending to the thalamus.
  • An urgent ventriculoperitoneal shunt was inserted, and chemotherapy was given to reduce the tumor size.
  • The tumor was completely excised 2 months after diagnosis with improvement of clinical signs and symptoms.
  • These were progressive pineal gland tumor enlargement documented on MRI without increase in previously elevated alpha-fetoprotein levels.
  • The tumor continued to enlarge despite gamma knife radiosurgery.
  • Secondary parkinsonism is a rare presentation of pineal gland tumors and has not been reported in association with the growing teratoma syndrome.
  • [MeSH-major] Parkinsonian Disorders / etiology. Pinealoma / diagnosis
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Disease Progression. Equipment Failure. Follow-Up Studies. Humans. Hydrocephalus / diagnosis. Hydrocephalus / etiology. Image Enhancement. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Ventriculoperitoneal Shunt

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12849888.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Hanna A, Edan C, Heresbach N, Ben Hassel M, Guegan Y: [Expanding mature pineal teratoma syndrome. Case report]. Neurochirurgie; 2000 Dec;46(6):568-572
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT scan showed a pineal region tumor with obstructive hydrocephalus.
  • After CSF (cerebrospinal fluid) shunting, MRI showed that the tumor had a heterogenous signal enhancement.
  • The tumor marker HCG (human chorionic gonadotrophin) was elevated in CSF and serum.
  • After three cycles of chemotherapy, MRI showed an important increase in tumor size with morphologic modifications.
  • On postoperative MRI, there was a small area of signal enhancement of the left thalamus.
  • The child was in complete remission 15 months after the diagnosis.
  • Growing teratoma syndrome is a mixed germ cell tumor with a secreting portion that responds to chemotherapy and a non secreting portion of mature teratoma that continues to grow under chemotherapy.
  • The treatment should include chemotherapy for the malignant secreting portion and surgery for the mature teratoma.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cerebrospinal Fluid Shunts. Chorionic Gonadotropin / blood. Chorionic Gonadotropin / cerebrospinal fluid. Chorionic Gonadotropin / secretion. Combined Modality Therapy. Diagnosis, Differential. Diplopia / etiology. Etoposide / administration & dosage. Germinoma / diagnosis. Humans. Ifosfamide / administration & dosage. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Proteins / blood. Neoplasm Proteins / cerebrospinal fluid. Neoplasm Proteins / secretion. Radiotherapy, Adjuvant. Remission Induction. Thalamus / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11148410.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; 0 / Neoplasm Proteins; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Siffert J, Allen JC: Late effects of therapy of thalamic and hypothalamic tumors in childhood: vascular, neurobehavioral and neoplastic. Pediatr Neurosurg; 2000 Aug;33(2):105-11
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects of therapy of thalamic and hypothalamic tumors in childhood: vascular, neurobehavioral and neoplastic.
  • The late effects in children with hypothalamic and thalamic tumors relate to the effects of the tumor on the surrounding brain, the effects of surgery, radiotherapy (RT) and, to a lesser extent, chemotherapy.
  • The prevention of late effects is an integral part of current treatment strategies.
  • Early diagnosis, a rational use of surgery, and deferral of RT are the mainstays of the modern treatment in these patients.
  • The improvement of RT techniques and the use of radioprotective compounds may further help spare normal brain tissue.
  • A better understanding of chemotherapy use and the development of newer agents may increase efficacy, reduce side effects and allow deferral of RT in a greater percentage of patients.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Hypothalamus / pathology. Hypothalamus / radiation effects. Neoplasms, Radiation-Induced / pathology. Thalamus / pathology. Thalamus / radiation effects. Visual Pathways / pathology. Visual Pathways / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel.
  • (PMID = 11070438.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O, Hernáiz-Driever P, Théallier-Janko A, Zintl F, Längler A, Wolff JE, Csatary LK: Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS; 2006 Oct;114(10):731-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid.
  • The case of a 12-year-old boy with anaplastic astrocytoma of the left thalamus is reported.
  • Postoperative irradiation and chemotherapy could not repress tumor progression; therefore, treatment was undertaken with an oncolytic virus, MTH-68/H, an attenuated strain of Newcastle disease virus (NDV), and valproic acid (VPA), an antiepileptic drug, which also has antineoplastic properties.
  • This treatment resulted in a far-reaching regression of the thalamic glioma, but 4 months later a new tumor manifestation, an extension of the thalamic tumor, appeared in the wall of the IVth ventricle, which required a second neurosurgical intervention.
  • Under continuous MTH-68/H - VPA administration the thalamic tumor remained under control, but the rhombencephalic one progressed relentlessly and led to the fatal outcome.
  • In the final stage, a third tumor manifestation appeared in the left temporal lobe.
  • The possible reasons for the antagonistic behavior of the three manifestations of the same type of glioma to the initially most successful therapy are discussed.
  • The comparative histological study of the thalamic and rhombencephalic tumor manifestations revealed that MTH-68/H treatment induces, similar to in vitro observations, a massive apoptotic tumor cell decline.
  • In the rhombencephalic tumor, in and around the declining tumor cells, NDV antigen could be demonstrated immunohistochemically, and virus particles have been found in the cytoplasm of tumor cells at electron microscopic investigation.
  • These findings document that the oncolytic effect of MTH-68/H treatment is the direct consequence of virus presence and replication in the neoplastic cells.
  • [MeSH-major] Anticonvulsants / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / therapy. Brain Neoplasms / therapy. Valproic Acid / therapeutic use. Viral Vaccines / therapeutic use
  • [MeSH-minor] Administration, Oral. Antigens, Viral / analysis. Antigens, Viral / metabolism. Brain / virology. Child. Combined Modality Therapy. Cytoplasm / virology. Fatal Outcome. Humans. Male. Newcastle disease virus / immunology. Recurrence. Thalamus / pathology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004977.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antigens, Viral; 0 / Newcastle disease virus vaccine MTH-68-H; 0 / Viral Vaccines; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


17. Yokoo H, Kamiya M, Sasaki A, Hirato J, Nakazato Y, Kurachi H: Neurofibromatosis type 1-associated unusual pleomorphic astrocytoma displaying continual malignant progression. Pathol Int; 2001 Jul;51(7):570-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1-associated unusual pleomorphic astrocytoma displaying continual malignant progression.
  • Patients with neurofibromatosis type 1 (NF1) often have gliomas as a complication, most of which are benign pilocytic astrocytomas which have arisen in optic pathways.
  • In the present case, a 17-year-old girl (at death) with stigmata of NF1, initially had a bulky tumor mass in the left thalamus, developing into the lateral ventricle, at 13 years of age.
  • Partially resected tissue samples showed pleomorphic astrocytoma with abundant xanthoma cells and degenerative structures such as Rosenthal fibers (RF) and eosinophilic granular bodies.
  • The residual tumor was subtotally resected 6 months later, and the tumor histology was essentially similar as before, accompanying the regenerative structures; this was believed to be a good prognostic indicator.
  • After a 2-year, disease-free interval, multiple tumor relapse occurred in June 1997.
  • Partially resected tumor tissues were composed of monotonous small anaplastic cells with prominent proliferative activity.
  • Surprisingly, the tumor cells had retained eosinophilic granules within the cell bodies.
  • Postoperative chemotherapy with procarbazine, MCNU and vincristine (PCV) suppressed the residual tumor dramatically, but the regrowing tumor finally became uncontrollable, leading to the patient's death.
  • A review of previously published reports failed to reveal any cases of this type.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Muscle Proteins. Neurofibromatosis 1 / pathology. Thalamus / pathology
  • [MeSH-minor] Adolescent. Antigens, Nuclear. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA Primers / chemistry. DNA, Neoplasm / analysis. Fatal Outcome. Female. Humans. Microfilament Proteins / analysis. Neoplasm Recurrence, Local. Neoplasms, Second Primary / pathology. Nitrosourea Compounds / therapeutic use. Nuclear Proteins / analysis. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Procarbazine / therapeutic use. Tumor Suppressor Protein p53 / analysis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11472572.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Nitrosourea Compounds; 0 / Nuclear Proteins; 0 / Tagln protein, mouse; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; RYH2T97J77 / ranimustine
  •  go-up   go-down


18. Scrigni A, Nastri M, Rodríguez de Schiavi S, Czornyj L, Felice M, Mantese B: Leptomeningeal lymphoma in a child with acquired immune deficiency syndrome. Neuropediatrics; 2006 Jun;37(3):121-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a seven-year-old HIV-infected boy, in stage C3 of the disease, who developed non-Hodgkin lymphoma in the central nervous system with a leptomeningeal location.
  • The diagnosis was based on brain biopsy, immunophenotypic studies of B cells, and Epstein-Barr virus serology of the cerebrospinal fluid.
  • The boy was treated with intrathecal and systemic chemotherapy.
  • Fifteen months after diagnosis he had clinically improved, but he then relapsed with a thalamic tumor.
  • In the present article, we discuss diagnostic difficulties, evolution, treatment, and the association of this neoplasm with the Epstein-Barr virus.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, Non-Hodgkin / etiology. Meningeal Neoplasms / etiology


19. Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA, Xiong X, Wu S, Merchant TE: Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab; 2003 Feb;88(2):611-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for the development of obesity in children surviving brain tumors.
  • Hypothalamic obesity, a syndrome of intractable weight gain due to hypothalamic damage, is an uncommon but devastating complication for children surviving brain tumors.
  • We undertook a retrospective evaluation of the body mass index (BMI) curves for the St. Jude Children's Research Hospital brain tumor population diagnosed between 1965 and 1995 after completion of therapy to determine risk factors for the development of obesity.
  • Inclusion criteria were: diagnosis less than 14 yr of age, no spinal cord involvement, ambulatory, no supraphysiologic hydrocortisone therapy (>12 mg/m(2) x d), treatment and follow-up at St. Jude Children's Research Hospital, and disease-free survival greater than 5 yr (n = 148).
  • Risk factors examined were age at diagnosis, tumor location, histology, extent of surgery, hydrocephalus requiring ventriculoperitoneal shunting, initial high-dose glucocorticoids, cranial radiation therapy, radiation dosimetry to the hypothalamus, intrathecal chemotherapy, and presence of endocrinopathy.
  • Risk factors were: age at diagnosis (P = 0.04), radiation dosimetry to the hypothalamus (51-72 Gy, P = 0.002 even after hypothalamic and thalamic tumor exclusion), and presence of any endocrinopathy (P = 0.03).
  • In addition, risk factors when compared with BMI slope for the general American pediatric population included: tumor location (hypothalamic, P = 0.001), tumor histology (craniopharyngioma, P = 0.009; pilocytic astrocytoma, P = 0.043; medulloblastoma, P = 0.039); and extent of surgery (biopsy, P = 0.03; subtotal resection, P = 0.018).
  • These results verify hypothalamic damage, either due to tumor, surgery, or radiation, as the primary cause of obesity in survivors of childhood brain tumors.
  • In particular, hypothalamic radiation doses of more than 51 Gy are permissive.
  • These results reiterate the importance of the hypothalamus in energy balance, provide risk assessment criteria for preventative measures before the development of obesity in at-risk patients, and suggest therapeutic strategies to reduce the future development of obesity.
  • [MeSH-major] Brain Neoplasms / epidemiology. Craniopharyngioma / epidemiology. Obesity / epidemiology
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / epidemiology. Astrocytoma / radiotherapy. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / epidemiology. Cerebellar Neoplasms / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Humans. Hypothalamus / physiology. Medulloblastoma / drug therapy. Medulloblastoma / epidemiology. Medulloblastoma / radiotherapy. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12574189.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / P30CA12765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


20. Schmid I, Stachel D, Graubner UB, Elsner R, Schulze S, Pöllinger B, Goetz C, Haas RJ: [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature]. Klin Padiatr; 2005 May-Jun;217(3):153-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature].
  • [Transliterated title] Supratentorieller primitiver neuroektodermaler Tumor: Erfahrungen in einem Zentrum im Vergleich zur Literatur.
  • Supratentorial primitive neuroectodermal tumors (stPNETs) are malignant tumors.
  • All had craniospinal irradiation and chemotherapy according to the HIT-91 protocol.
  • The two children with incomplete resection died due to tumor progression after 7 and 10 months.
  • Two of the 4 children with complete tumor resection had local relapses 8 months after diagnosis and died after 14 and 18 months.
  • One child had a diffuse meningeal relapse 12 months after diagnosis.
  • Despite (high-dose) systemic chemotherapy and intraventricular mafosfamide, he died 21 months after diagnosis due to tumor although remission could be achieved.
  • Only one child is still in remission 86 months after diagnosis.
  • [MeSH-major] Brain Neoplasms. Cerebellar Nuclei. Corpus Callosum. Frontal Lobe. Neuroectodermal Tumors. Occipital Lobe. Parietal Lobe. Temporal Lobe. Thalamus
  • [MeSH-minor] Brain Stem Neoplasms / secondary. Cerebellar Neoplasms / mortality. Cerebellar Neoplasms / surgery. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Humans. Male. Mesencephalon. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858707.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Sterzing F, Grehn C, Dinkel J, Krempien R, Hartung G, Debus J, Harms W: Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. Strahlenther Onkol; 2007 Sep;183(9):487-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After a cumulative dose of 240 mg/m(2) the patient suddenly became somnolent and developed a severe tetraparesis and generalized seizures.
  • After symptomatic treatment on the intensive care unit all symptoms were completely reversible.
  • CONCLUSION: Toxic encephalopathy is a rare but dramatic complication of various cytostatic drugs.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / adverse effects. Neurotoxicity Syndromes / etiology. Radiation-Sensitizing Agents / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Brachytherapy / adverse effects. Caudate Nucleus / drug effects. Caudate Nucleus / pathology. Combined Modality Therapy. Diffusion Magnetic Resonance Imaging. Epilepsy, Generalized / chemically induced. Epilepsy, Generalized / diagnosis. Female. Follow-Up Studies. Humans. Middle Aged. Midline Thalamic Nuclei / drug effects. Midline Thalamic Nuclei / pathology. Neoplasm Staging. Neurologic Examination / drug effects. Occipital Lobe / drug effects. Occipital Lobe / pathology. Radioisotope Teletherapy / adverse effects. Remission, Spontaneous. Thalamus / drug effects. Thalamus / pathology. Tomography, X-Ray Computed


22. Hill MD, Mackenzie I, Mason WP: Radiation-induced glioma presenting as diffuse leptomeningeal gliomatosis: a case report. J Neurooncol; 2001 Nov;55(2):113-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He later developed an enhancing thalamic tumor arising within the treatment field of a remotely irradiated pituitary adenoma.
  • Subsequent management included chemotherapy and further radiotherapy with transient response, before death from leptomeningeal and parenchymal tumor progression 16 months after diagnosis.
  • Our patient's course is novel in that symptomatic relief was achieved with CSF diversion and a combination of chemotherapy and focal radiation allowed prolonged survival.
  • [MeSH-major] Adenoma / radiotherapy. Glioma / diagnosis. Meningeal Neoplasms / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Pituitary Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cerebrospinal Fluid Shunts. Combined Modality Therapy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1986 Aug;19(2):247-51 [3748352.001]
  • [Cites] Br J Cancer. 1992 Dec;66(6):999-1004 [1457369.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] Neurology. 1996 Jun;46(6):1760-2 [8649589.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):392-7 [1845944.001]
  • [Cites] Can J Neurol Sci. 1985 Aug;12 (3):278-81 [4052890.001]
  • [Cites] Neurology. 1984 Dec;34(12):1611-5 [6390250.001]
  • [Cites] J Neuropathol Exp Neurol. 1951 Jan;10(1):16-29 [14804124.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):393-6 [9007876.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] J Comput Assist Tomogr. 1993 Mar-Apr;17(2):317-20 [8454762.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1994;6(6):361-3 [7873481.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):45-9 [8455062.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • [Cites] Rev Neurol (Paris). 1995 Mar;151(3):177-89 [7676154.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):471-3 [8163998.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] BMJ. 1992 Jul 25;305(6847):253-4 [1392843.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • (PMID = 11817701.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Sasayama T, Mizukawa K, Sakagami Y, Mizowaki T, Tanaka K, Ohbayashi C, Mori K, Kitazawa S, Kohmura E: Glioblastoma multiforme associated with klinefelter syndrome. Neurol Med Chir (Tokyo); 2009 Nov;49(11):532-5
MedlinePlus Health Information. consumer health - Klinefelter's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging showed multiple heterogeneously enhanced tumors in the bilateral frontal lobes.
  • Angiography showed no tumor stain or arteriovenous shunt.
  • The tumor was partially removed through a right craniotomy.
  • The histological diagnosis was glioblastoma.
  • Postoperative local radiotherapy (60 Gy/30 fractions) combined with temozolomide (75 mg/m(2) x 42 days) and interferon-beta (3,000,000 U, 3 times/week) was performed.
  • The patient's clinical status rapidly deteriorated during chemoradiotherapy, and he died of tumor progression 3.5 months after the surgery.
  • Postmortem examination revealed widespread glioblastoma infiltrating the basal ganglia and thalamus.
  • Klinefelter syndrome is associated with increased cancer predisposition, especially for male breast cancer and germ cell tumors, but glioma is extremely rare.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioblastoma / genetics. Glioblastoma / pathology. Klinefelter Syndrome / complications. Klinefelter Syndrome / genetics
  • [MeSH-minor] Basal Ganglia / pathology. Craniotomy. Disease Progression. Drug Therapy. Fatal Outcome. Frontal Lobe / pathology. Frontal Lobe / surgery. Genetic Predisposition to Disease / genetics. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Neurosurgical Procedures. Paraparesis / etiology. Radiotherapy. Thalamus / pathology. Treatment Failure

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Klinefelter syndrome.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940404.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Yamada K, Takeshima H, Sakurama T, Kuratsu J: Secondary cervical dystonia following stereotactic radiosurgery in a patient with thalamic glioma. Surg Neurol; 2007 Dec;68(6):665-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary cervical dystonia following stereotactic radiosurgery in a patient with thalamic glioma.
  • We report the first patient with secondary CD after stereotactic radiosurgery for thalamic glioma.
  • CASE DESCRIPTION: A 27-year-old woman complaining of headache and left motor weakness was found to have a thalamic tumor on the right side.
  • Histopathologically, tumor samples manifested features of anaplastic astrocytoma.
  • She underwent stereotactic radiosurgery in addition to the conventional radiation and chemotherapy.
  • Sixteen months postoperatively, the patient developed forced head tilting to the left side combined with chin lift.
  • Irregular-shaped lesion involving the thalamus, lenticular nuclei, midbrain, pons, and cerebellum was presented on magnetic resonance images.
  • Steroid therapy effectively diminished the lesion size, and her abnormal head posturing was gradually ameliorated (TWSTRS severity scale = 3).
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Postoperative Complications / etiology. Radiosurgery / adverse effects. Torticollis / etiology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Necrosis. Thalamus / pathology. Thalamus / surgery


25. Hadjipanayis CG, Kondziolka D, Gardner P, Niranjan A, Dagam S, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary. J Neurosurg; 2002 Jul;97(1):56-64
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary.
  • OBJECT: The goal of this study was to examine the role of stereotactic radiosurgery in the treatment of patients with recurrent or unresectable pilocytic astrocytomas.
  • METHODS: During a 13-year interval, 37 patients (median age 14 years) required multimodal treatment of recurrent or unresectable pilocytic astrocytomas.
  • Tumors involved the brainstem in 18 patients, cerebellum in three, thalamus in five, temporal lobe in four, and parietal lobe in two, as well as the hypothalamus, optic tract, corpus callosum, insular cortex, and third ventricle in one patient each.
  • Diagnosis was confirmed with the aid of stereotactic biopsy in 12 patients, open biopsy in five, partial resection in eight, and near-total resection in 12.
  • Multimodal treatment included fractionated radiation therapy in 10 patients, stereotactic intracavitary irradiation of tumor in four, chemotherapy in two, cyst drainage in six, ventriculoperitoneal shunt placement in three, and additional cytoreductive surgery in four.
  • Tumor volumes varied from 0.42 to 25 cm3.
  • The median radiosurgical dose to the tumor margin was 15 Gy (range 9.6-22.5 Gy).
  • After radiosurgery, serial imaging demonstrated complete tumor resolution in 10 patients, reduced tumor volume in eight, stable tumor volume in seven, and delayed tumor progression in 12.
  • No procedure-related death was encountered.
  • Thirty-three (89%) of 37 patients are alive at a median follow-up period of 28 months after radiosurgery and 59 months after diagnosis.
  • Three patients died of local tumor progression.
  • Despite the favorable histological characteristics and prognosis usually associated with this neoplasm, an adverse location, recurrence, or progression of this disease requires alternative therapeutic approaches such as radiosurgery.
  • [MeSH-major] Astrocytoma / surgery. Astrocytoma / therapy. Brain Stem Neoplasms / surgery. Brain Stem Neoplasms / therapy. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cysts / surgery. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Radiotherapy / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134933.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement